January 30, 2024 07:35 AM ESTUpdated 11:39 AM
Deals

Cor­rect­ed: 2sev­en­ty bio sells R&D unit to Re­gen­eron for $5M up­front, cuts ad­di­tion­al staff

Lei Lei Wu

News Reporter

Af­ter a rough year, 2sev­en­ty bio is tak­ing ex­treme mea­sures. The blue­bird bio spin­out is sell­ing its en­tire R&D pipeline to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times